FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366210400> ?p ?o ?g. }

• W4366210400 endingPage "e006567" @default.
• W4366210400 startingPage "e006567" @default.
• W4366210400 abstract "Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. However, CD47 is ubiquitously expressed and mediates functional interactions with other ligands as well, and therefore targeting of the primarily myeloid cell-restricted inhibitory immunoreceptor SIRPα may represent a better strategy. Method We generated BYON4228, a novel SIRPα-directed antibody. An extensive preclinical characterization was performed, including direct comparisons to previously reported anti-SIRPα antibodies. Results BYON4228 is an antibody directed against SIRPα that recognizes both allelic variants of SIRPα in the human population, thereby maximizing its potential clinical applicability. Notably, BYON4228 does not recognize the closely related T-cell expressed SIRPγ that mediates interactions with CD47 as well, which are known to be instrumental in T-cell extravasation and activation. BYON4228 binds to the N-terminal Ig-like domain of SIRPα and its epitope largely overlaps with the CD47-binding site. BYON4228 blocks binding of CD47 to SIRPα and inhibits signaling through the CD47-SIRPα axis. Functional studies show that BYON4228 potentiates macrophage-mediated and neutrophil-mediated killing of hematologic and solid cancer cells in vitro in the presence of a variety of tumor-targeting antibodies, including trastuzumab, rituximab, daratumumab and cetuximab. The silenced Fc region of BYON4228 precludes immune cell-mediated elimination of SIRPα-positive myeloid cells, implying anticipated preservation of myeloid immune effector cells in patients. The unique profile of BYON4228 clearly distinguishes it from previously reported antibodies representative of agents in clinical development, which either lack recognition of one of the two SIRPα polymorphic variants (HEFLB), or cross-react with SIRPγ and inhibit CD47-SIRPγ interactions (SIRPAB-11-K322A, 1H9), and/or have functional Fc regions thereby displaying myeloid cell depletion activity (SIRPAB-11-K322A). In vivo, BYON4228 increases the antitumor activity of rituximab in a B-cell Raji xenograft model in human SIRPα BIT transgenic mice. Finally, BYON4228 shows a favorable safety profile in cynomolgus monkeys. Conclusions Collectively, this defines BYON4228 as a preclinically highly differentiating pan-allelic SIRPα antibody without T-cell SIRPγ recognition that promotes the destruction of antibody-opsonized cancer cells. Clinical studies are planned to start in 2023." @default.
• W4366210400 created "2023-04-19" @default.
• W4366210400 creator A5002725927 @default.
• W4366210400 creator A5003861851 @default.
• W4366210400 creator A5006427874 @default.
• W4366210400 creator A5016047466 @default.
• W4366210400 creator A5016699736 @default.
• W4366210400 creator A5018940783 @default.
• W4366210400 creator A5021026753 @default.
• W4366210400 creator A5023282085 @default.
• W4366210400 creator A5023504692 @default.
• W4366210400 creator A5027591048 @default.
• W4366210400 creator A5027856560 @default.
• W4366210400 creator A5029181928 @default.
• W4366210400 creator A5034234365 @default.
• W4366210400 creator A5035984434 @default.
• W4366210400 creator A5039629685 @default.
• W4366210400 creator A5043988410 @default.
• W4366210400 creator A5045328771 @default.
• W4366210400 creator A5047985151 @default.
• W4366210400 creator A5048722299 @default.
• W4366210400 creator A5050145609 @default.
• W4366210400 creator A5050665402 @default.
• W4366210400 creator A5051689129 @default.
• W4366210400 creator A5052540098 @default.
• W4366210400 creator A5066489599 @default.
• W4366210400 creator A5067209823 @default.
• W4366210400 creator A5068899074 @default.
• W4366210400 creator A5071373994 @default.
• W4366210400 creator A5072106249 @default.
• W4366210400 creator A5073452219 @default.
• W4366210400 creator A5076917735 @default.
• W4366210400 creator A5079613205 @default.
• W4366210400 creator A5081138173 @default.
• W4366210400 creator A5082203343 @default.
• W4366210400 date "2023-04-01" @default.
• W4366210400 modified "2023-10-18" @default.
• W4366210400 title "BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells" @default.
• W4366210400 cites W1495576644 @default.
• W4366210400 cites W1522869792 @default.
• W4366210400 cites W1925857700 @default.
• W4366210400 cites W1957657505 @default.
• W4366210400 cites W1964757399 @default.
• W4366210400 cites W1972581358 @default.
• W4366210400 cites W1990908331 @default.
• W4366210400 cites W1998665610 @default.
• W4366210400 cites W2002220495 @default.
• W4366210400 cites W2009465985 @default.
• W4366210400 cites W2017098129 @default.
• W4366210400 cites W2018917333 @default.
• W4366210400 cites W2028033239 @default.
• W4366210400 cites W2033911003 @default.
• W4366210400 cites W2035070408 @default.
• W4366210400 cites W2035759169 @default.
• W4366210400 cites W2039949492 @default.
• W4366210400 cites W2041944580 @default.
• W4366210400 cites W2057796048 @default.
• W4366210400 cites W2068052762 @default.
• W4366210400 cites W2083359402 @default.
• W4366210400 cites W2083545980 @default.
• W4366210400 cites W2091133773 @default.
• W4366210400 cites W2092328154 @default.
• W4366210400 cites W2094502174 @default.
• W4366210400 cites W2106415942 @default.
• W4366210400 cites W2106545303 @default.
• W4366210400 cites W2117281169 @default.
• W4366210400 cites W2127122881 @default.
• W4366210400 cites W2133346943 @default.
• W4366210400 cites W2139418176 @default.
• W4366210400 cites W2141253335 @default.
• W4366210400 cites W2150087633 @default.
• W4366210400 cites W2152192278 @default.
• W4366210400 cites W2168109319 @default.
• W4366210400 cites W2205886515 @default.
• W4366210400 cites W2302839786 @default.
• W4366210400 cites W2339658610 @default.
• W4366210400 cites W2550646651 @default.
• W4366210400 cites W2594014934 @default.
• W4366210400 cites W2605934824 @default.
• W4366210400 cites W2626117210 @default.
• W4366210400 cites W2744546677 @default.
• W4366210400 cites W2770192040 @default.
• W4366210400 cites W2784099979 @default.
• W4366210400 cites W2793275933 @default.
• W4366210400 cites W2795318100 @default.
• W4366210400 cites W2811247652 @default.
• W4366210400 cites W2899044337 @default.
• W4366210400 cites W2911699089 @default.
• W4366210400 cites W2953392779 @default.
• W4366210400 cites W2993915621 @default.
• W4366210400 cites W3026871210 @default.
• W4366210400 cites W3089940214 @default.
• W4366210400 cites W3092910755 @default.
• W4366210400 cites W3109590960 @default.
• W4366210400 cites W3118507153 @default.
• W4366210400 cites W3119498457 @default.
• W4366210400 cites W3165579721 @default.
• W4366210400 cites W3197752237 @default.

• next